Peptide PilotPeptide Pilot
Download on the App Store

Comparison

AOD-9604 vs Tesamorelin

AOD-9604 (a hGH fragment studied for fat metabolism) against tesamorelin (GHRH analog studied for visceral fat) — two different mechanisms, same broad question.

Download on the App StoreiPhone · Free to download
Field
AOD-9604
Tesamorelin
Category
Fat loss
GH Secretagogue
Common alias
Lipolytic fragment of hGH
—
Example vial
5 mg + 2 mL BAC water
5 mg + 2 mL BAC water
Concentration
2.50 mg/mL
2.50 mg/mL
Example dose
0.3 mg
1 mg
Doses per week
7× / week
7× / week
Doses per vial (rounded down)
16
5
Approx vial duration
2.3 weeks
0.7 weeks

AOD-9604 and Tesamorelin both show up in the same conversations, but they aren't interchangeable. The table above lays the vial math side by side so you can see how concentration, doses-per-vial, and weekly cadence actually compare. The sections below walk through what each one is, how each is studied, and how each shows up in a tracked log — in plain English, no recommendations.

Tiebreakers

Where AOD-9604 and Tesamorelin actually diverge

AOD-9604Tesamorelin
Cadence7/wk7/wk
Concentration on example2.50 mg/mL2.50 mg/mL
Math weeks per vial2.30.7
CategoryFat lossGH Secretagogue

Bolded values are the higher of the two on numeric rows. Same-value rows aren't a verdict — they're shared properties.

AOD-9604 vs Tesamorelin: the actual decision

These two molecules are stacked together in the comparison hub because the search-intent question is the same — adipose-tissue-targeted protocols — even though the mechanisms are completely different. AOD-9604 is a synthetic fragment of human growth hormone (the C-terminal 16 amino acids) that was developed specifically to retain hGH's lipolytic effect without the broader IGF-1-mediated growth signal. Tesamorelin is a stabilized GHRH analog that drives endogenous GH release; the visceral-fat reduction effect is downstream of that broader GH signal rather than the direct lipolytic mechanism AOD-9604 was designed for.

Studied population matters here. Tesamorelin has a relatively mature evidence base because it is approved for HIV-associated lipodystrophy and was studied extensively for visceral adipose tissue reduction in that population. AOD-9604 has a thinner human evidence base; the lipolytic effect is well-supported in the preclinical work but the human trials in obesity were less definitive. A reader weighing the two molecules is also implicitly weighing the depth of the published clinical data behind each.

Mechanism, cadence, and what shows up in a log

Cadence is very different between the two molecules. AOD-9604 protocols are typically once-daily subcutaneous at doses around 250–500 mcg; tesamorelin protocols are typically once-daily subcutaneous at doses around 1–2 mg. The per-dose milligram gap is roughly 4-to-1 in tesamorelin's favor, which means a vial of either molecule at the same concentration empties at very different rates. The vial-duration calculator linked below shows the difference at your own example vials.

Logging the two molecules is structurally similar — daily administration, waist circumference and body composition as the most-tracked endpoints, the usual fasting-glucose and morning-energy proxies that go with any GH-pathway protocol. The difference shows up in the fields that matter: an AOD-9604 log centers on the lipolytic endpoint alone because the molecule was designed to isolate that effect; a tesamorelin log usually also tracks the broader GH-signal proxies because the mechanism produces them whether you want them or not.

AOD-9604 vs Tesamorelin: the numbers, side by side

Start with what actually goes into a syringe. The example AOD-9604 vial on this site reconstitutes 5 mg in 2 mL of bacteriostatic water — about 2.50 mg per mL, which yields roughly 16 doses at the 0.3 mg example and lasts about 2.3 weeks at 7 doses per week. The example Tesamorelin vial reconstitutes 5 mg in 2 mL (2.50 mg/mL), which yields about 5 doses at 1 mg and stretches roughly 0.7 weeks at 7 doses per week. Those numbers are the starting point most people forget to write down, and they decide everything downstream — refill timing, unit count on the syringe barrel, and whether a 30-mL bac-water bottle stretches across one vial or two.

Category context matters too. AOD-9604 is a Fat loss molecule; Tesamorelin is a GH Secretagogue molecule. People comparing them are usually deciding between two different mechanisms aimed at overlapping goals, which is a more structural choice than two molecules in the same family — the side-by-side table above puts the vial math in the same units so the comparison is direct. Cadence helps frame the rest: AOD-9604 is logged about 7× per week in the example schedule, Tesamorelin about 7×.

The single most-asked-about mistake on each page is worth surfacing here, because they rarely overlap. On the AOD-9604 side: Shaking the vial like a protein shake after adding water, which can damage the peptide. On the Tesamorelin side: Assuming the per-dose volume and syringe draw will be as small as sermorelin's and failing to plan for a larger subcutaneous injection. Both are the kind of thing a tracked log catches early and an untracked routine catches late.

Top AOD-9604 question
What is AOD-9604 and how is it different from HGH?

AOD-9604 is a small, modified piece of human growth hormone (HGH). It was created to isolate the fat-burning properties of HGH without affecting growth, muscle-building, or insulin levels, as it does not bind to the primary HGH receptor.

Top Tesamorelin question
Why is the Tesamorelin dose in milligrams (mg) when other GHRH analogs are often dosed in micrograms (mcg)?

Tesamorelin's milligram-level dosing is a function of its molecular structure and the extensive clinical research that established its use profile. As the full 44-amino-acid GHRH sequence, its molecular weight and receptor affinity necessitate a larger mass to achieve the desired level of pituitary stimulation. The protocols for its FDA-approved indication were developed around a 1 mg or 2 mg daily dose, reflecting its distinct pharmacology compared to smaller, truncated peptide fragments.

The calculator pages linked below let you swap your own vial size, diluent volume, and dose into the same math — these example numbers exist so the comparison renders with concrete figures instead of placeholders.

Frequently asked questions about AOD-9604 vs Tesamorelin

What is AOD-9604 and how is it different from HGH?
AOD-9604 is a small, modified piece of human growth hormone (HGH). It was created to isolate the fat-burning properties of HGH without affecting growth, muscle-building, or insulin levels, as it does not bind to the primary HGH receptor.
What is AOD-9604 commonly tracked for?
People use AOD-9604 to support fat metabolism and body composition goals. It is studied for its potential ability to stimulate the breakdown of existing fat (lipolysis) and inhibit the formation of new fat cells (lipogenesis).
When do people typically administer AOD-9604?
It is most commonly used first thing in the morning on an empty stomach. Users often wait at least 30-60 minutes before eating to allow the peptide to work without potential interference from a rise in insulin levels.
Why is the Tesamorelin dose in milligrams (mg) when other GHRH analogs are often dosed in micrograms (mcg)?
Tesamorelin's milligram-level dosing is a function of its molecular structure and the extensive clinical research that established its use profile. As the full 44-amino-acid GHRH sequence, its molecular weight and receptor affinity necessitate a larger mass to achieve the desired level of pituitary stimulation. The protocols for its FDA-approved indication were developed around a 1 mg or 2 mg daily dose, reflecting its distinct pharmacology compared to smaller, truncated peptide fragments.
What specifically is the purpose of the trans-3-hexenoyl group on Tesamorelin?
The trans-3-hexenoyl group is a fatty acid-based modification chemically bonded to the start of the peptide chain. Its sole purpose is to serve as a physical shield, sterically hindering the enzyme DPP-IV from accessing its cleavage site on the GHRH sequence. This protection from enzymatic degradation is what grants Tesamorelin a significantly longer half-life compared to native GHRH, which is its primary design advantage.
Using a 5 mg vial reconstituted with 2 mL of water, how many units would a 1 mg dose be?
When a 5 mg vial is reconstituted with 2 mL of bacteriostatic water, the solution's final concentration is 2.5 mg/mL. To obtain a 1 mg dose from this solution, you would need to draw 0.40 mL. On any standard U-100 insulin syringe, a volume of 0.40 mL is equivalent to exactly 40 units.

Related on Peptide Pilot

Log AOD-9604 and Tesamorelin side by side in the app

Download on the App StoreiPhone · Free · No credit card
Download on theApp Store→